Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure

FOLFIRINOX (FX) and gemcitabine (GEM) plus nab-paclitaxel (GnP) have been reported as effective regimens for unresectable advanced pancreatic cancer (APC). FX may be more effective but is also associated with more adverse events (AEs). Therefore, first-line treatment with FX followed by second-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Mita, Naoki, Iwashita, Takuji, Uemura, Shinya, Yoshida, Kensaku, Iwasa, Yuhei, Ando, Nobuhiro, Iwata, Keisuke, Okuno, Mitsuru, Mukai, Tsuyoshi, Shimizu, Masahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616879/
https://www.ncbi.nlm.nih.gov/pubmed/31146420
http://dx.doi.org/10.3390/jcm8060761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616879/
https://www.ncbi.nlm.nih.gov/pubmed/31146420
http://dx.doi.org/10.3390/jcm8060761

Ejemplares similares